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The 5'-triphosphates of 1-(2'-deoxy-2'-fluoro-j-D-arabinofuranosyl)-5-methyluracil, 1-(2'-deoxy-2'-fluoro-
P-D-arabinofuranosyl)-5-iodocytosine, 1-(2'-deoxy-2'-fluoro-p-D-arabinofuranosyl)-5-methylcytosine, 94(2-
hydroxyethoxy)methyl]guanine, and 9-(1,3-dihydroxy-2-propoxymethyl)guanine had lower Ki values for
Epstein-Barr virus DNA polymerase than has been reported elsewhere for host DNA polymerase. Inhibition of
DNA elongation by these analogs ranged from moderate to strong, suggesting that preferential incorporation
of these analogs into DNA by virus DNA polymerase may contribute to antiviral selectivity.
Epstein-Barr virus (EBV), a member of the herpesvirus
family, is recognized as an important human pathogen and is
closely associated with certain human malignancies (10, 11,
15). Thus, it would be useful to develop selective anti-EBV
compounds. The approach taken in this laboratory is to
design compounds based on the unique properties of virus-
specified enzymes (2, 5). EBV is known to induce its own
specific DNA polymerase (8, 14, 18). The properties of this
EBV-specified enzyme are in many ways similar to the
properties of herpes simplex virus (HSV) DNA polymerase,
which are different from those of human DNA polymerases
(1, 8, 9, 14, 19). It is logical, therefore, to consider EBV
DNA polymerase as a target for developing anti-EBV agents.
Acyclovir (ACV) has been shown to have potent anti-
EBV activity, although the action was readily reversible
upon removal of ACV from the culture medium (6, 7). The
action of ACV against EBV replication was suggested to be
due to inhibition of EBV DNA polymerase by ACV-tri-
phosphate (ACVTP), which is a potent inhibitor that com-
petes with dGTP for binding to EBV DNA polymerase (7).
In addition to the ability to be preferentially phosphorylated
by HSV-specified thymidine kinase, several triphosphates of
anti-HSV nucleoside analogs have higher binding affinities to
HSV type 1 (HSV-1) and HSV-2 DNA polymerase than to
human enzymes (3, 9, 12, 13), which could contribute to
their selectivity of action against HSV. Based on the simi-
larity of herpesvirus DNA polymerases, it is conceivable
that some of these anti-HSV nucleoside analogs also have a
selective anti-EBV activity, possibly caused by preferential
interaction ofEBV DNA polymerase with their triphosphate
metabolites. Thus, we examined the effect of several anti-
HSV nucleoside analogs against EBV replication in culture.
1-(2'-deoxy-2'-fluoro-,-D-arabinofuranosyl)-5-methyluracil
(FMAU), 1-(2'-deoxy-2'-fluoro-,-D-arabinofuranosyl)-5-
iodocytosine (FIAC), and 9-(1,3-dihydroxy-2-propoxymeth-
yl)guanine (DHPG) are potent inhibitors of EBV replication
at noncytotoxic concentrations, and their antiviral activity is
quite irreversible (4, 16). Since the anti-EBV activity of
these nucleoside analogs could be due to their preferential
interaction with EBV DNA polymerase once they are
phosphorylated, the effects of FMAUTP, FIACTP, the
5'-triphosphate of 1-(2'-deoxy-2'-fluoro-,-D-arabinofurano-
syl)-5-methylcytosine (FMACTP), DHPGTP, and ACVTP
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on EBV DNA polymerase were examined. The enzyme used
was highly purified according to procedures described pre-
viously by us to a specific activity of more than 4.0 x 105
U/mg of protein (20). The preparations of FMAUTP,
FIACTP, FMACTP, DHPGTP, and ACVTP were previ-
ously published (13, 19). The results are shown in Table 1. It
was found that FMAUTP, FIACTP, FMACTP, DHPGTP,
and ACVTP could inhibit the incorporation of dTTP, dCTP,
dCTP, dGTP, and dGTP, respectively, into DNA templates
catalyzed by EBV DNA polymerase. The Ki values for EBV
DNA polymerase were lower than those for human a and ,B
DNA polymerases (9, 13, 19). Our results with ACVTP were
similar to those reported previously (Ki value of 15 nM) (7),
whereas the results with FIACTP were significantly different
from the Ki value of 32.2 puM reported by Allaudeen et al.
(1). It is unclear why there was such a difference. The
observation that Ki values for these compounds were lower
against EBV DNA polymerase than against human DNA
polymerase is consistent with our hypothesis and could be
part of the reason for their selective anti-EBV action. The
efficiency of triphosphate metabolite formation from these
analogs in EBV-carrying cells is under investigation. To
further investigate the action of these analogs on the EBV
DNA polymerase-catalyzed reaction, we performed studies
to examine whether each of these analogs could substitute
for its competing deoxynucleoside triphosphate (dNTP),
which is required for support of DNA chain elongation. The
results-are shown in Fig. 1. The drug or deoxynucleotide
used was present at a concentration fivefold higher than the
Km or Ki value described in Table 1. FMAUTP, FIACTP,
and FMACTP could partially substitute for their competing
deoxynucleotides in DNA chain elongation. This suggested
that these analogs could be incorporated; however, the rate
of further chain elongation was slow relative to the control
rate. The incorporation of FIAC into DNA by HSV-1 or
HSV-2 DNA polymerase was reported previously (1, 19).
DHPGTP or ACVTP, instead of stimulating DNA synthesis
in the absence of dGTP, inhibited the DNA chain elongation
catalyzed by EBV DNA polymerase. These results are
similar to those obtained when the interaction of DHPGTP
or ACVTP with HSV DNA polymerase was examined (9,
13). These results suggest that the mode of action of both
compounds with EBV DNA polymerase is the same as with
HSV DNA polymerase. Both ACVTP and DHPGTP can be
incorporated into the DNA template; however, the DHPG-
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TABLE 1. Inhibition constants of analog dNTPs for EBV DNA
polymerasea
Compound Km, (p.M) of K jM ,,Kcompeting substrate Kj (M) KmK1
FMAUTP 0.64 ± 0.13 (dTTP) 0.08 ± 0.005 8.0
FIACTP 0.52 ± 0.04 (dCTP) 0.95 ± 0.07 1.5
FMACTP 0.51 ± 0.04 (dCTP) 0.9 ± 0.14 0.6
DHPGTP 0.58 ± 0.08 (dGTP) 0.08 ± 0.02 7.3
ACVTP 0.58 ± 0.08 (dGTP) 0.007 ± 0.002 82.9
a Analog dNTPs were prepared as described previously (13, 19). Km values
were determined from Lineweaver-Burk plots with five different concentra-
tions of variable dNTP. Ki values were determined by replotting Lineweaver-
Burk plots which employed three drug concentrations. All compounds were
assayed concurrently against radioactive competing substrates in amounts 0.3
to 2.0 times the Km. Noncompeting dNTPs were present at 100 ,uM each. The
assay conditions were as described previously (9), except that 150 mM KCI
was added instead of 200 mM. Purified enzyme (0.16 U) was used for each
assay. The assays had a reaction time of 20 min at 37°C. One unit of enzyme
activity catalyzed the incorporation of 1 pmol of dATP per min in the absence
of inhibitor.
terminated DNA is poorly elongated, whereas the ACV-ter-
minated DNA is not elongated at all. In addition, ACV- or
DHPG-terminated DNA could interfere with the DNA poly-
merase action by competing with unsubstituted DNA tem-
plates. Obtaining final proof of this hypothesis will require
an analog with high radiospecificity.
In summary, our studies suggest that these analogs are
preferentially incorporated into DNA by EBV DNA polymer-
ase, which could be part of the mechanism responsible for
their selective anti-EBV action. Since ACV was incorpo-
rated only at the termini of growing DNA chains, whereas
FMAU, FIAC, FMAC, and DHPG were incorporated in
both terminal and internal positions, this could be part of the
reason why the anti-EBV actions of FMAU, FIAC, and
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FIG. 1. Effect of analog dNTPs on limited DNA synthesis cata-
lyzed by EBV DNA polymerase. Synthesis of DNA by EBV DNA
polymerase was assayed by using conditions identical to those
described in Table 1, except that one dNTP (dCTP, dGTP, or dTTP)
was omitted. Reaction mixtures contained 10 ,uM [3H]dATP (2
,uCi/nmol), two other dNTPs at 100 ,uM each, and 0.16 U of EBV
DNA polymerase. The effect of adding back the missing dNTP at a
concentration fivefold above the Km value or adding a dNTP analog
at a concentration fivefold above the Ki value was examined.
Symbols: (A) 0, no dTTP or analog added; 0, dTTP added; A,
FMAUTP added; (B) 0, no dCTP or analog added; 0, dCTP added;
A, FIACTP added; A, FMACTP added; (C) 0, no dGTP or analog
added; 0, dGTP added; A, DHPGTP added; A, ACVTP added.
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